Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 3, Issue 2, 2009, Pages 97-102

  Shafti, Saeed Shoja ^a  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

Author keywords

Fluphenazine decanoate; Olanzapine; Poorly responsive schizophrenia

Indexed keywords

FLUPHENAZINE DECANOATE; OLANZAPINE; PLACEBO;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; EVALUATION AND FOLLOW UP; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOM; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOM; SCHEDULE FOR ASSESSMENT OF INSIGHT; SCHIZOPHRENIA; SCORING SYSTEM; SIMPSON ANGUS SCALE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 70349229549     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.3.2.4     Document Type: Article

References (23)

1. Sadock BJ, Sadock VA. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. p. 471-504.
2. Kane JM, Marder SR. Schizophrenia: somatic treatment. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's comprehensive textbook of psychiatry. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. p. 1467-1476.
3. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-1132. (Pubitemid 41070972)
4. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al.; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160(8):1396-1404. (Pubitemid 41070913)
5. Dossenbach MR, Folnegovic-Smalc V, Hotujac L, Uglesic B, Tollefson GD, Grundy SL, et al.; HGCH Study Group. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(2):311-318.
6. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161(6):985-995. (Pubitemid 38735984)
7. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al.; Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162(5):947-953.
8. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63(6):622-629. (Pubitemid 43848293)
9. Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003;160(8):1514-1516.
10. Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006;10(17): iii-iv, ix-xi, 1-165. (Pubitemid 43940726)
11. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second- generation and depot antipsychotics. Ann Clin Psychiatry 2003;15(1):23-31. (Pubitemid 36723638)
12. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66(5):638-641.
13. Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry 2007;19(2):65-71. (Pubitemid 47035947)
14. Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23(3):299-314. (Pubitemid 40663635)
15. Martín J, Gómez JC, García-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997;58(11):479-483. (Pubitemid 27527443)
16. Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol 2001;21(4):448-453. (Pubitemid 32673036)
17. Chiu NY, Yang YK, Chen PS, Chang CC, Lee IH, Lee JR. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. Psychiatry Clin Neurosci 2003;57(5):478-484. (Pubitemid 37247742)
18. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63(10):931-935. (Pubitemid 35231734)
19. Battaglia J, Wolff TK, Wagner-Johnson DS, Rush AJ, Carmody TJ, Basco MR. Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol 1999;14(6):361-372. (Pubitemid 29531386)
20. Abhijnhan A, Adams CE, David A, Ozbilen M. Depot fluspirilene for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001718. DOI: 10.1002/14651858.CD001718.pub2.
21. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD000307. DOI: 10.1002/14651858. CD000307.
22. Green B. Focus on olanzapine. Curr Med Res Opin 1999;15(2):79-85.
23. Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999;19(7):811-822.